Harpoon Therapeutics Growth, Revenue, Number of Employees and Funding

Overview

Location:
Total Funding:$223.2M
Industry:Pharma
Founded:2015
Lead Investor(s):OrbiMed
Press

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Harpoon Therapeutics's estimated revenue is currently $4.8M per year.
  • Harpoon Therapeutics received $70.0M in venture funding in November 2018.
  • Harpoon Therapeutics's estimated revenue per employee is $81897
  • Harpoon Therapeutics's total funding is $223.2M.

Employee Data

  • Harpoon Therapeutics has 58 Employees.
  • Harpoon Therapeutics grew their employee count by 29% last year.
  • Harpoon Therapeutics currently has 10 job openings.

Executive Contacts

NameTitle
Mark WessonDirector, CMC Outsourcing
Natalie SacksChief Medical Officer
Che-Leung LawVP, Translational Medicine
Georgia ErbezChief Financial Officer
Christopher WhitmoreVice President Finance
Rachael LesterVP Corporate Development
Sue HirabayashiSr. Director, Clinical Operations
Grace WangAssociate Director
William PichtChief Financial Officer
Gerald McMahonPresident & CEO

What Is Harpoon Therapeutics?

Harpoon Therapeutics is a clinical stage biotechnology company co-founded by Patrick Bauerle, a pioneer in T-cell engagement, and Luke Evnin (MPM Capital) in 2015 to develop and commercialize a novel class of T cell recruiting antibodies engage a patient's own immune cells to fight cancer and other diseases. The world-class team of protein engineers and immunologists at Harpoon have built upon the successful development of the bispecific (BiTE or bispecific T cell engager) antibody Blincyto® to create a next-generation company dedicated to the development of novel non-antibody biologic therapies with improved efficacy and broad applicability in the treatment of human cancers and other life-altering diseases of the immune system. Harpoon's tri-specific T-cell redirection platform -- TriTAC -- was designed to address the needs of cancer patients not being met by current checkpoint inhibitors, bi-specifics, CAR-T and other T-cell engaging approaches by improving activity against solid tumors convenience of administration treatment of more tumor types and other immunologic diseases. Harpoon has discovered proprietary drug candidates and has an expansive research portfolio leveraging the TriTAC platform. Harpoon plans to file its first 2 INDs and initiate its first clinical study in 2018. Harpoon Therapeutics recently completed a Series B financing round with investors: MPM Capital, New Leaf Venture Partners, Arix Biosciences, and Taiho Ventures.

keywords:N/A

58

Number of Employees

$4.8M

Revenue (est)

10

Current Jobs

29%

Employee Growth %

$223.2M

Total Funding

N/A

Valuation

N/A

Accelerator

N/A

Type

Similar Companies

NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
Trifecta Clinic...
$12.3M653%
Rancho BioScien...
$10.1M5423%
Tlc Pharmacy
$8M435%
Otsuka America
$10.7M5719%
endpoint Clinic...
$55.9M29710%
GCAM
$17.9M954%
ZO Skin Health
$55.5M2952%
Teledyne Hanson...
$8.4M4515%
VIVUS
$19.3M1038%
AmeriPharma
$8.4M455%

Harpoon Therapeutics News

09/03/2019 - Harpoon Therapeutics to Participate in Two Upcoming ...

SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage ...

09/08/2019 - Analysts Expect Harpoon Therapeutics (HARP) Stock to Rise 74%; Rated Strong Buy

Harpoon Therapeutics Inc (HARP) stock has fallen -2.14% since Thursday, February 7, 2019 when Harpoon Therapeutics Inc began trading.

09/03/2019 - Harpoon Therapeutics, Inc. (HARP) Fell By -1.0%, And Here's Why

In its latest trading session, Harpoon Therapeutics, Inc. (HARP) dropped by -1.0% – here is what that looked like (as of 2019-09-06): ...

Harpoon Therapeutics Funding

DateAmountRoundLead InvestorsReference
2017-05-26$45.0MBArix BioscienceArticle
2018-11-12$70.0MCOrbiMedArticle

Harpoon Therapeutics Executive Hires

DateNameTitleReference
2017-05-05Che-Leung LawVP TRANSLATIONAL MEDICINEArticle
2017-10-27Susan JonesSVP product developmentArticle
2018-09-19Chris WhitmoreVP FinanceArticle
2018-10-04Natalie SacksChief Medical OfficerArticle
2018-10-31Georgia ErbezChief Financial OfficerArticle